Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evalua ...
A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phase A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evalua ...
A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phase A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evalua ...